Jessie Becker, co-founder and CEO of InPress Technologies, and Surbhi Sarna, founder and CEO of nVision Medical, both made the Forbes “30 Under 30” list.
Our companies-in-residence make incredible strides in advancing medical technology on a daily basis and it is highly rewarding when their hard efforts are recognized by both the medical and business communities.
Recently, Jessie Becker co-founder and CEO of InPress Technologies, made the Forbes annual “30 Under 30” list, which identifies the best and brightest innovators. Jessie is the second honoree from the Fogarty Institute to receive the award — Surbhi Sarna, founder and CEO of nVision Medical, made the list in 2014. Both women were among a handpicked group of entrepreneurs recognized for shaping the future of healthcare.
InPress is developing a simple device that is intended to quickly and effectively stop postpartum hemorrhage (PPH), which is the leading cause of maternal death globally, taking the life of one woman every four minutes. Early results of the company’s clinical trial in Jakarta, Indonesia, have been 100 percent successful. The company has already raised $1.5 million in seed money.
Jessie and Surbhi benefit from sharing ideas at the Fogarty Institute’s Fog Shop, where the companies-in-residence reside.
nVision is an early-stage, venture-backed medical device company that is dedicated to filling the void in female health-related innovation. It is currently developing catheter-based diagnostic devices for non-invasive cell retrieval, as well as for detection of fallopian tube blockage — the leading cause of infertility in women. nVision is engaging with the FDA this year.
“We are energized by the progress in medical device innovation made by our early-stage companies, and it is a great distinction that two of our entrepreneurs have been chosen by Forbes for their pioneering role in advancing healthcare,” said Anne Fyfe, president and CEO of the Fogarty Institute for Innovation. “Both of these young women are very deserving of the Forbes recognition, and we look forward to continuing to champion medical innovation for the unmet needs of women and newborns.”